•  
  •  
 

Subject Area

Clinical Pathology

Article Type

Original Study

Abstract

Objective To demonst rate whether BCL-2 (-938C>A) polymorphism can act as a modifier in diffuse large B-cell lymphoma (DLBCL) development and to identify its prognostic significance. Background DLBCL is the most common type of B non-Hodgkin lymphoma. The functional BCL-2-938C>A promoter polymorphism is proved to influence the balance between apoptosis and survival of malignant lymphoid cells. We looked at its usefulness as a susceptibility factor and its prognostic impact in the disease course. Patients and methods The BCL-2 (-938C>A) was genotyped in blood samples of 66 non-Hodgkin lymphoma patients of DLBCL type and 40 age-matched and sex-matched controls using the restricted fragment length polymorphism technique. Results We found that homozygous AA and heterozygous AC genotypes were associated with an increased risk for DLBCL development against the CC genotype by 4.33-fold and 3.89-fold, respectively. A allele versus c allele and AA, AC genotypes versus CC genotype showed significantly higher distribution among DLBCL patients than the control. No significant association was observed between different genotypes and tumor characteristics. No significant association was found between any of the genotypes and disease-free survival or overall survival rates. Conclusions AA and AC genotypes of BCL-2 (-938C>A) is associated with susceptibility for DLBCL development; however, this single-nucleotide polymorphism did not influence neither the clinical parameters nor the patient survival.

Download

Share

COinS